Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein

The objectives of this non-randomized, non-blinded, dose-escalating Phase I clinical trial were to assess the safety, reactogenicity and immunogenicity of ICC-1132 formulated with Alhydrogel (aluminum hydroxide) in 51 healthy, malaria-naive adults aged 18 to 45 years. ICC-1132 (Malariavax) is a reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregson, Aric L., Oliveira, Giane, Othoro, Caroline, Calvo-Calle, J. Mauricio, Thorton, George B., Nardin, Elizabeth, Edelman, Robert
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216688/
https://www.ncbi.nlm.nih.gov/pubmed/18253503
http://dx.doi.org/10.1371/journal.pone.0001556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216688/
https://www.ncbi.nlm.nih.gov/pubmed/18253503
http://dx.doi.org/10.1371/journal.pone.0001556

Ejemplares similares